Novartis is investing in a novel type of medicine to reduce the risk of heart disease.

The majority of Europeans can’t identify the warning signs of heart failure, a life threatening disease, which affects one in five people in the region.

Our Global Head of Patient Affairs and Policy shares why it’s critical to engage patients throughout the drug development process.

Doyle describes the road to improving patient outcomes across Europe through the HARMONY Alliance.

Melanoma survivor T.J. Sharpe discusses skin cancer prevention and detection, and shares tips on how to keep you and your loved ones safe in the sun.